Difference between revisions of "Buserelin (Suprefact)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | [[Category:Nasal medications]] | ||
| + | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
[[Category:EMA approved in 1984]] | [[Category:EMA approved in 1984]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 12:50, 27 July 2023
Mechanism of action
Gonadotropin-releasing hormone (GnRH) analog, inhibits pituitary gonadotropin secretion, which suppresses ovarian and testicular steroidogenesis.
Diseases for which it is used
History of changes in EMA indication
- EURD: 1984-08-16
Also known as
- Code names: HOE 766, ICI 123215, S74-6766
- Brand names: Bigonist, Etilamide, Profact, Receptal, Suprecur, Suprefact